In the BioHarmony Drug Report Database

"Preview" Icon

Silodosin

Rapaflo, Silodyx, Urorec (silodosin) is a small molecule pharmaceutical. Silodosin was first approved as Rapaflo on 2008-10-08. It is used to treat prostatic hyperplasia in the USA. It has been approved in Europe to treat prostatic hyperplasia. The pharmaceutical is active against alpha-1A adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor and alpha-1D adrenergic receptor.

 

Trade Name

 

Silodyx, Urorec
 

Common Name

 

silodosin
 

ChEMBL ID

 

CHEMBL24778
 

Indication

 

prostatic hyperplasia
 

Drug Class

 

Image (chem structure or protein)

Silodosin structure rendering